Publications by authors named "Robert T Higginson"
Article Synopsis
- Long-acting cabotegravir/rilpivirine (CAB/RPV) is primarily used for HIV patients who are already virologically suppressed, but recent cases show it can be effective for those with detectable viral loads.
- The study discusses two patients with multidrug resistance who struggled with oral therapy due to adherence issues and swallowing problems, but achieved viral suppression after switching to CAB/RPV with lenacapavir injections.
- The findings suggest that injectable ART like CAB/RPV combined with LEN could be a promising treatment alternative for patients facing major challenges with traditional oral therapies.
Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Am J Health Syst Pharm
November 2011
Purpose: The pharmacokinetic interaction of etravirine and raltegravir is reviewed, with discussion of implications for clinical practice.
Summary: Etravirine (a second-generation nonnucleoside reverse transcriptase inhibitor) and raltegravir (an integrase strand- transfer inhibitor) are two agents approved by the Federal Food and Drug Administration for use in human immunodeficiency virus (HIV) treatment-resistant patients. Minimal data exist on the concurrent use of raltegravir with etravirine.
Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) has resulted in significant morbidity and mortality reductions. Lifelong antiretroviral therapy must be incorporated into each patient's medical regimen. Patients with HIV may also have simultaneous chronic medical conditions, resulting in the possibility of complex drug-drug interactions.
View Article and Find Full Text PDFObjective: To report a case of pancreatitis associated with the combined use of didanosine and tenofovir.
Case Summary: A 51-year-old white man with HIV was initiated on antiretroviral therapy with didanosine 250 mg/day, tenofovir 300 mg/day, lamivudine 300 mg/day, stavudine 60 mg/day, and efavirenz 600 mg/day. Didanosine was prescribed at a reduced dosage due to the known interaction with tenofovir.